| |
 |
API and Intermediates |
| |
Varenicline Intermediates |
| |
7,8,9,10-tetrahydro-6,10-Methano-6H-pyrazino[2,3-h][3]benzazepine |
| |
2,2,2-trifluoro-1-(6,7,9,10-tetrahydro-6,10-methano-8H-pyrazino[2,3-h][3]benzazepin-8-yl)ethanone |
| |
1-(7,8-diamino-1,2,4,5-tetrahydro-1,5-methano-3H-3-benzazepin-3-yl)-2,2,2-trifluoroethanone |
| |
1-(7,8-dinitro-1,2,4,5-tetrahydro-1,5-methano-3H-3-benzazepin-3-yl)-2,2,2-trifluoroethanone |
| |
2,2,2-trifluoro-1-(1,2,4,5-tetrahydro-1,5-methano-3H-3-benzazepin-3-yl)ethanone |
| |
Atazanavir Intermediates |
| |
Hydrazinecarboxylic acid, 2-[[4-(2-pyridinyl)phenyl]methyl]-, 1,1-dimethylethyl ester |
| |
Hydrazinecarboxylic acid, 2-[(2S,3S)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]-, 1,1-dimethylethyl ester |
| |
2R,3S)-3-(tert-Butoxycarbonyl)amino-1,2-epoxy-4-phenylbutane£¬Carbamic acid, N-[(1S)-1-(2R)-2-oxiranyl-2-phenylethyl]-, 1,1-dimethylethyl ester |
| |
Lapatinib Intermediates |
| |
Lapatinib Base,N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine |
| |
5-formyl-2-furanylboronic acid |
| |
2-(methylsulfonyl)Ethanamine hydrochloride |
| |
5-[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-Furancarboxaldehyde |
| |
Ritonavir Intermediates |
| |
(2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino -3-hydroxy -1,6-diphenylhexane 1/2 succinate |
| |
1-(2-isopropylthiazol-4-yl)-N-methyl methanamine |
| |
(S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido) -3-methylbutanoic acid |
| |
(2S,3S,5S)-5-amino-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane |
| |
5-thiazolylmethyl 4-nitrophenylcarbonate, monohydrochloride |
| |
Boc-Phe-OH |
| |
N-[(1S,2S,4S)-4-amino-2-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]-2-(2,6-dimethylphenoxy)acetamide |
| |
2,6-dimetylphenoxyacetic acid |
| |
Sitagliptin Intermediates |
| |
Sitagliptin |
| |
[[(1,1-dimethylethoxy)carbonyl]amino]-2,4,5-trifluoro-(R)-benzenebutanoic acid |
| |
Erlotinib Intermediates |
| |
methyl ester, 4,5-bis(2-methoxyethoxy)-2-nitrobenzoic acid |
| |
methyl ester,2-amino-4,5-bis(2-methoxyethoxy)benzoic acid |
| |
6,7-bis(2-methoxyethoxy)-4(3H)-Quinazolinone |
| |
4-chloro-6,7-bis(2-methoxyethoxy)quinazoline |
None of the products will be supplied to countries in which this could be in conflict with the existing patents. However the final responsibility lies with the Buyer. | |